{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T21:27:18Z","timestamp":1744061238001,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005565","name":"Janssen Global Services, LLC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s12325-022-02226-x","type":"journal-article","created":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T10:02:44Z","timestamp":1658743364000},"page":"4230-4249","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed\/Refractory Multiple Myeloma"],"prefix":"10.1007","volume":"39","clinical-trial-number":[{"clinical-trial-number":"nct03180736","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02136134","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01998971","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5015-3713","authenticated-orcid":false,"given":"Jianming","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Berringer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"Heeg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoyao","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Kampfenkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harikumaran R.","family":"Dwarakanathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sacheeta","family":"Bathija","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma K.","family":"Mackay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,22]]},"reference":[{"key":"2226_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"2226_CR2","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046\u201360.","journal-title":"N Engl J Med"},{"key":"2226_CR3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397:410\u201327.","journal-title":"Lancet"},{"key":"2226_CR4","first-page":"5","volume":"4","author":"S Kurtin","year":"2013","unstructured":"Kurtin S. Relapsed or relapsed\/refractory multiple myeloma. J Adv Pract Oncol. 2013;4:5\u201314.","journal-title":"J Adv Pract Oncol"},{"key":"2226_CR5","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","volume":"10","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10:94.","journal-title":"Blood Cancer J"},{"key":"2226_CR6","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1182\/asheducation-2017.1.508","volume":"2017","author":"P Sonneveld","year":"2017","unstructured":"Sonneveld P. Management of multiple myeloma in the relapsed\/refractory patient. Hematology Am Soc Hematol Educ Program. 2017;2017:508\u201317.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2226_CR7","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Multiple Myeloma, Version 5.2022. 2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf. Accessed 13 Jan 2022."},{"key":"2226_CR8","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1158\/2643-3230.BCD-21-0028","volume":"2","author":"G Lancman","year":"2021","unstructured":"Lancman G, Sastow DL, Cho HJ, et al. Bispecific antibodies in multiple myeloma: present and future. Blood Cancer Discov. 2021;2:423\u201333.","journal-title":"Blood Cancer Discov"},{"key":"2226_CR9","doi-asserted-by":"publisher","first-page":"e446","DOI":"10.1016\/S2352-3026(21)00057-0","volume":"8","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Usmani SZ, Yong K. CAR T-cell therapy for multiple myeloma: state of the art and prospects. Lancet Haematol. 2021;8:e446\u201361.","journal-title":"Lancet Haematol"},{"key":"2226_CR10","doi-asserted-by":"publisher","first-page":"807","DOI":"10.4049\/jimmunol.1501351","volume":"197","author":"MB Overdijk","year":"2016","unstructured":"Overdijk MB, Jansen JH, Nederend M, et al. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcgamma receptor-mediated cross-linking. J Immunol. 2016;197:807\u201313.","journal-title":"J Immunol"},{"key":"2226_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1037","volume":"3","author":"G Salanti","year":"2012","unstructured":"Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. 2012;3:80\u201397.","journal-title":"Res Synth Methods"},{"key":"2226_CR12","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","volume":"22","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M, et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase\u00a03 trial. Lancet Oncol. 2021;22:801\u201312.","journal-title":"Lancet Oncol"},{"key":"2226_CR13","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:754\u201366.","journal-title":"N Engl J Med"},{"key":"2226_CR14","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","volume":"130","author":"A Chari","year":"2017","unstructured":"Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma. Blood. 2017;130:974\u201381.","journal-title":"Blood"},{"key":"2226_CR15","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/0962280210394483","volume":"21","author":"E Williamson","year":"2012","unstructured":"Williamson E, Morley R, Lucas A, Carpenter J. Propensity scores: from naive enthusiasm to intuitive understanding. Stat Methods Med Res. 2012;21:273\u201393.","journal-title":"Stat Methods Med Res"},{"key":"2226_CR16","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46:399\u2013424.","journal-title":"Multivar Behav Res"},{"key":"2226_CR17","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1353\/obs.2018.0012","volume":"4","author":"G Visconti","year":"2018","unstructured":"Visconti G, Zubizarreta J. Handling limited overlap in observational studies with cardinality matching. Observ Stud. 2018;4:217\u201349.","journal-title":"Observ Stud"},{"key":"2226_CR18","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1080\/01621459.2012.703874","volume":"107","author":"J Zubizarreta","year":"2012","unstructured":"Zubizarreta J. Using mixed integer programming for matching in an observational study of kidney failure after surgery. J Am Stat Assoc. 2012;107:1360\u201371.","journal-title":"J Am Stat Assoc"},{"key":"2226_CR19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jama.2021.20555","volume":"327","author":"BA Niknam","year":"2022","unstructured":"Niknam BA, Zubizarreta JR. Using cardinality matching to design balanced and representative samples for observational studies. JAMA. 2022;327:173\u20134.","journal-title":"JAMA"},{"key":"2226_CR20","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28:3083\u2013107.","journal-title":"Stat Med"},{"key":"2226_CR21","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1214\/13-AOAS713","volume":"8","author":"J Zubizarreta","year":"2014","unstructured":"Zubizarreta J, Paredes RD, Rosembaum P. Matching for balance, pairing for heterogeneity in an observational study of the effectiveness of for-profit and not-for-profit high schools in Chile. Ann Appl Stat. 2014;8:204\u201331.","journal-title":"Ann Appl Stat"},{"key":"2226_CR22","unstructured":"Phillipo D, Ades A, Dias S, Palmer S, Abrams K, NJ W. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE. http:\/\/nicedsu.org.uk\/wp-content\/uploads\/2018\/08\/Population-adjustment-TSD-FINAL-ref-rerun.pdf Accessed 13 Jan 2022."},{"key":"2226_CR23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","volume":"70","author":"P Robak","year":"2018","unstructured":"Robak P, Drozdz I, Szemraj J, Robak T. Drug resistance in multiple myeloma. Cancer Treat Rev. 2018;70:199\u2013208.","journal-title":"Cancer Treat Rev"},{"key":"2226_CR24","doi-asserted-by":"publisher","first-page":"E63","DOI":"10.1016\/j.clml.2017.03.115","volume":"17","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA, Weisel K, Kaufman JL, et al. Efficacy and safety of daratumumab-based regimens in patients with relapsed\/refractory multiple myeloma\u2014a systematic literature review and network meta-analysis. Clin Lymphoma Myeloma Leuk. 2017;17:E63.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2226_CR25","doi-asserted-by":"publisher","first-page":"21916","DOI":"10.1038\/s41598-021-01440-x","volume":"11","author":"S Kiss","year":"2021","unstructured":"Kiss S, Gede N, Hegyi P, et al. Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials. Sci Rep. 2021;11:21916.","journal-title":"Sci Rep"},{"key":"2226_CR26","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.2147\/CMAR.S166640","volume":"10","author":"XW Luo","year":"2018","unstructured":"Luo XW, Du XQ, Li JL, Liu XP, Meng XY. Treatment options for refractory\/relapsed multiple myeloma: an updated evidence synthesis by network meta-analysis. Cancer Manag Res. 2018;10:2817\u201323.","journal-title":"Cancer Manag Res"},{"key":"2226_CR27","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1016\/j.jval.2021.11.180","volume":"25","author":"X Leleu","year":"2022","unstructured":"Leleu X, Delea T, Guyot P, Moynahan A, Singh E, Lin P. Comparative efficacy and safety of isatuximab plus pomalidomide and dexamethasone versus daratumumab plus pomalidomide and dexamethasone in patients with multiple myeloma using a matching-adjusted indirect comparison. Value Health. 2022;25:S39 (POSC34).","journal-title":"Value Health"},{"key":"2226_CR28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11899-019-0495-9","volume":"14","author":"SA Holstein","year":"2019","unstructured":"Holstein SA, Suman VJ, McCarthy PL. Should overall survival remain an endpoint for multiple myeloma trials? Curr Hematol Malig Rep. 2019;14:31\u20138.","journal-title":"Curr Hematol Malig Rep"},{"key":"2226_CR29","doi-asserted-by":"publisher","first-page":"PA408","DOI":"10.1016\/j.jval.2017.08.064","volume":"20","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA, Sonneveld P, Nahi H, et al. Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma. Value Health. 2017;20:PA408.","journal-title":"Value Health"},{"key":"2226_CR30","unstructured":"US Food and Drug Administration. Table\u00a0of surrogate endpoints that were the basis of drug approval or licensure. https:\/\/www.fda.gov\/drugs\/development-resources\/table-surrogate-endpoints-were-basis-drug-approval-or-licensure Accessed 17 Nov 2021."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02226-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02226-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02226-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T09:09:32Z","timestamp":1710148172000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02226-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,22]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["2226"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02226-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2022,7,22]]},"assertion":[{"value":"14 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}